Induction of APOBEC3B cytidine deaminase in HTLV‑1‑infected humanized mice

Yao,Jinchun; Tanaka,Masakazu; Takenouchi,Norihiro; Ren,Yihua; Lee,Sung‑Il; Fujisawa,Jun‑Ichi

doi:10.3892/etm.2019.7375

Induction of APOBEC3B cytidine deaminase in HTLV‑1‑infected humanized mice

Authors:
- Jinchun Yao
- Masakazu Tanaka
- Norihiro Takenouchi
- Yihua Ren
- Sung‑Il Lee
- Jun‑Ichi Fujisawa
View Affiliations

Affiliations: Department of Microbiology, Kansai Medical University, Hirakata, Osaka 573‑1010, Japan, Institute of Biomedical Science, Kansai Medical University, Hirakata, Osaka 573‑1010, Japan
Published online on: March 13, 2019 https://doi.org/10.3892/etm.2019.7375
Pages: 3701-3708

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human T‑cell leukemia virus type 1 (HTLV‑1) is the causative agent of adult T‑cell leukemia/lymphoma (ATL). Following viral infection with HTLV‑1, certain infected cells exhibit clonal proliferation. Additional genetic and epigenetic changes in these clonally proliferating cells provide them with the selective advantage of growth, which eventually results in ATL. The precise mechanism, however, has yet to be completely elucidated. It has previously been established that APOBEC3 enzymes are potent host‑antiviral restriction factors. Conversely, previous studies have reported that the A3B level is increased in tumor virus infections, such as those caused by HBV and HPV, suggesting that A3B exerts a function as a mutagen. Therefore, the present study analyzed the expression of APOBEC3 family members in various HTLV‑1 infection states. No significant differences were observed in the expression between healthy donors and patients with HTLV‑1‑associated myelopathy. Although no significant changes in the expressions of A3C, A3D, A3F and A3G between uninfected and HTLV‑1‑infected mice were observed, an increased A3B expression was observed in a short‑term humanized mouse model following HTLV‑1 infection. In a long‑term humanized mouse model following HTLV‑1 infection, the gene expression array data exhibited an apparent increase in A3B and CADM1, which are indicators of ATL. Collectively, the results of the present study suggest that A3B is likely involved in the development of ATL in HTLV‑1‑infected humanized mice.

View Figures

View References

1	Uchiyama T, Yodoi J, Sagawa K, Takatsuki K and Uchino H: Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood. 50:481–492. 1977.PubMed/NCBI
2	Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M and Tara M: HTLV-1 associated myelopathy, a new clinical entity. Lancet. 1:1031–1032. 1986. View Article : Google Scholar : PubMed/NCBI
3	Nakao K, Ohba N and Matsumoto M: Noninfectious anterior uveitis in patients infected with human T-lymphotropic virus type I. Jpn J Ophthalmol. 33:472–481. 1989.PubMed/NCBI
4	Clapham P, Nagy K, Cheingsong-Popov R, Exley M and Weiss RA: Productive infection and cell free transmission of human T-cell leukemia virus in a non-lymphoid cell line. Science. 222:1125–1127. 1983. View Article : Google Scholar : PubMed/NCBI
5	Derse D, Mikovits J, Polianova M, Felber BK and Ruscetti F: Virions released from cells transfected with a molecular clone of human T-cell leukemia virus type I give rise to primary and secondary infections of T cells. J Virol. 69:1907–1912. 1995.PubMed/NCBI
6	Fialkow PJ: Clonal original of human tumors. Annu Rev Med. 30:135–143. 1979. View Article : Google Scholar : PubMed/NCBI
7	Malim MH: APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci. 364:675–687. 2009. View Article : Google Scholar : PubMed/NCBI
8	Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, Kiezun A, Kryukov GV, Carter SL, Saksena G, et al: An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet. 45:970–976. 2013. View Article : Google Scholar : PubMed/NCBI
9	Burns MB, Temiz NA and Harris RS: Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet. 45:977–983. 2013. View Article : Google Scholar : PubMed/NCBI
10	Vartanian JP, Henry M, Marchio A, Suspène R, Aynaud MM, Guétard D, Cervantes-Gonzalez M, Battiston C, Mazzaferro V, Pineau P, et al: Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog. 6:e10009282010. View Article : Google Scholar : PubMed/NCBI
11	Vartanian JP, Guétard D, Henry M and Wain-Hobson S: Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science. 320:230–233. 2008. View Article : Google Scholar : PubMed/NCBI
12	Albin JS and Harris RS: Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: Implications for therapeutics. Expert Rev Mol Med. 12:e42010. View Article : Google Scholar : PubMed/NCBI
13	Tezuka K, Xun R, Tei M, Ueno T, Tanaka M, Takenouchi N and Fujisawa J: An animal model of adult T-cell leukemia: Humanized mice with HTLV-1-specific immunity. Blood. 123:346–355. 2014. View Article : Google Scholar : PubMed/NCBI
14	Nie C, Sato K, Misawa N, Kitayama H, Fujino H, Hiramatsu H, Heike T, Nakahata T, Tanaka Y, Ito M and Koyanagi Y: Selective infection of CD4⁺ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rgammanull mice. Virology. 394:64–72. 2009. View Article : Google Scholar : PubMed/NCBI
15	Salter JD, Bennett RP and Smith HC: The APOBEC protein family: United by structure, divergent in function. Trends Biochem Sci. 41:578–594. 2016. View Article : Google Scholar : PubMed/NCBI
16	Yoshida M, Suzuki T, Fujisawa J and Hirai H: HTLV-1 oncoprotein tax and cellular transcription factors. Curr Top Microbiol Immunol. 193:79–89. 1995.PubMed/NCBI
17	Furuta RA, Sugiura K, Kawakita S, Inada T, Ikehara S, Matsuda T and Fujisawa J: Mouse model for the equilibration interaction between the host immune system and human T-cell leukemia virus type 1 gene expression. J Virol. 76:2703–2713. 2002. View Article : Google Scholar : PubMed/NCBI
18	Yamano Y, Cohen CJ, Takenouchi N, Yao K, Tomaru U, Li HC, Reiter Y and Jacobson S: Increased expression of human T lymphocyte virus type I (HTLV–I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4⁺CD25⁺ T cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-1-associated neurologic disease. J Exp Med. 199:1367–1377. 2004. View Article : Google Scholar : PubMed/NCBI
19	Sasaki H, Nishikata I, Shiraga T, Akamatsu E, Fukami T, Hidaka T, Kubuki Y, Okayama A, Hamada K, Okabe H, et al: Overexpression of a cell adhesion molecule, TSLC1, as a possible molecular marker for acute-type adult T-cell leukemia. Blood. 105:1204–1213. 2005. View Article : Google Scholar : PubMed/NCBI
20	Araki K, Harada K, Nakamoto K, Shiroma M and Miyakuni T: Clinical significance of serum soluble IL-2R levels in patients with adult T cell leukaemia (ATL) and HTLV-1 carriers. Clin Exp Immunol. 119:259–263. 2000. View Article : Google Scholar : PubMed/NCBI
21	Henderson S and Fenton T: APOBEC3 genes: Retroviral restriction factors to cancer drivers. Trends Mol Med. 21:274–284. 2015. View Article : Google Scholar : PubMed/NCBI
22	Wang Y, Kinlock BL, Shao Q, Turner TM and Liu B: HIV-1 Vif inhibits G to A hypermutations catalyzed by virus-encapsidated APOBEC3G to maintain HIV-1 infectivity. Retrovirology. 11:892014. View Article : Google Scholar : PubMed/NCBI
23	Guerrero S, Libre C, Batisse J, Mercenne G, Richer D, Laumond G, Decoville T, Moog C, Marquet R and Paillart JC: Translational regulation of APOBEC3G mRNA by Vif requires its 5′UTR and contributes to restoring HIV-1 infectivity. Sci Rep. 6:395072016. View Article : Google Scholar : PubMed/NCBI
24	Fan J, Ma G, Nosaka K, Tanabe J, Satou Y, Koito A, Wain-Hobson S, Vartanian JP and Matsuoka M: APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo. J Virol. 84:7278–7287. 2010. View Article : Google Scholar : PubMed/NCBI
25	Ooms M, Krikoni A, Kress AK, Simon V and Munk C: APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. J Virol. 86:6097–6108. 2012. View Article : Google Scholar : PubMed/NCBI
26	Lamb C and Arbuthnot P: Activating the innate immune response to counter chronic hepatitis B virus infection. Expert Opin Biol Ther. 16:1517–1527. 2016. View Article : Google Scholar : PubMed/NCBI
27	Cardinaud S, Urrutia A, Rouers A, Coulon PG, Kervevan J, Richetta C, Bet A, Maze EA, Larsen M, Iglesias MC, et al: Triggering of TLR-3, −4, NOD2, and DC-SIGN reduces viral replication and increases T-cell activation capacity of HIV-infected human dendritic cells. Eur J Immunol. 47:818–829. 2017. View Article : Google Scholar : PubMed/NCBI
28	Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, Totoki Y, Chiba K, Sato-Otsubo A, Nagae G, et al: Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 47:1304–1315. 2015. View Article : Google Scholar : PubMed/NCBI
29	Vieira VC and Soares MA: The role of cytidine deaminases on innate immune responses against human viral infections. Biomed Res Int. 2013:6830952013. View Article : Google Scholar : PubMed/NCBI
30	Tajima K: The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: Estimates of risk of ATL and its geographical and clinical features. The T- and B-cell malignancy study group. Int J Cancer. 45:237–243. 1990. View Article : Google Scholar : PubMed/NCBI
31	Lairmore MD, Silverman L and Ratner L: Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformation. Oncogene. 24:6005–6015. 2005. View Article : Google Scholar : PubMed/NCBI
32	Zou J, Wang C, Ma X, Wang E and Peng G: APOBEC3B, a molecular driver of mutagenesis in human cancers. Cell Biosci. 7:292017. View Article : Google Scholar : PubMed/NCBI